Drug Profile


Alternative Names: BRL 38227; Levanex; Levcromakalim; Levro-cromakalim

Latest Information Update: 18 Jan 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Developer GlaxoSmithKline; Meiji Seika Kaisha
  • Class Antiasthmatics; Antihypertensives; Benzopyrans; Bronchodilators; Small molecules
  • Mechanism of Action KATP channel stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Arrhythmias; Asthma; Hypertension; Ischaemic heart disorders

Most Recent Events

  • 15 Oct 2002 No development reported - Preregistration for Hypertension in Japan (PO)
  • 23 Jan 2001 SmithKline Beecham has merged with Glaxo Wellcome to form GlaxoSmithKline
  • 16 Dec 1999 Profile reviewed, but no significant modifications made
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top